Loading…
← CockpitCompetitor Analysis › IMMX Immix Biopharma, Inc.Open in the cockpit ↗

Immix Biopharma, Inc.IMMXCompetitor analysis, valuation and peers

United States · USD·Health Care›Pharmaceuticals: Major
Momentum laggard 14
Mkt cap
$596M
US dollars, full cap
Free float
82%
of shares outstanding
$/day
$8.94M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
n/a
WACC 6.6%
Hurdle
n/a
no reverse DCF
Next earnings
105 days
3 Mar 2027
Close · USD$7.11
1D-1.2%
1W-17.9%
1M-20.2%
3M-46.0%
6M-20.5%
YTD+36.0%
1Y+76.0%
ATR %8.7%
Beta1.71
52w lowhigh52.9% off high

What Immix Biopharma does

Employees: 21

Immix Biopharma at a glance

Size Immix Biopharma (IMMX) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $596M, the 2556th largest of 3,085 United States companies the cockpit tracks. Shares closed at $7.11 on 18 Nov 2026.

Performance Over six months the shares fell 20.5%, against -31.3% for the median peer and -2.2% for the United States market (cap-weighted) — 7th highest of 20 in its peer set.

Next results Next results expected around 3 Mar 2027 (exchange calendar; dates can move).

Relative performance

10015021 May 202621 Aug 202618 Nov 2026IMMX 82Peer median 71
Six months, rebased to 100: Immix Biopharma against the median of its 20 peers (local-currency closes).

Immix Biopharma financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$0$0$0$0$0
Revenue growth—————
Gross profit-$467,861-$364,501-$115,388-$5,468-$2,135
EBITDA-$49.5M-$26.8M-$22.5M-$16.1M-$8.22M
Net income-$46.3M-$29.4M-$21.6M-$15.4M-$8.23M
Free cash flow-$45.2M-$24.7M-$15.8M-$11.4M-$7.41M
Capital expenditure$339,896$732,925$1.18M$52,089$0
Total debt$965,053$1.07M$1.07M$0$0

Quarterly statements and history in the cockpit →

Immix Biopharma competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-40%-20%0%+20%-25%0%+25%+50%600976300147301096300233DBVCGEM6034391857500029403001942157ORCHPHARMA410522563613OLMAIMMX6-month return →1-month return →
Up and to the right = strong over both horizons. Immix Biopharma is the large dot.

Immix Biopharma competitors and peer comparison

How Immix Biopharma compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Immix Biopharma against its 20 peers (data as of 18 Nov 2026)
MeasureIMMXPeer medianRank in peer set
1-month return-20.2%-11.5%3rd lowest of 20
6-month return-20.5%-31.3%7th highest of 20
Distance from 52-week high-52.9%-43.9%8th lowest of 20

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Immix Biopharma IMMXUnited States$596M-20%n/an/an/an/an/a
JIANMIN PHARMACEUTICAL 600976.SSChina$598M-14%-2%8%0.9×-6.2%+6.5%
Xiangxue Pharmaceutical 300147.SZChina$591M-41%+3%-39%3.7×50.4%-12.3%
Hangzhou Bio-Sincerity Pharma-Tech 301096.SZChina$602M-38%+5%-30%7.5×n/an/a
Shandong Jincheng Pharmaceutical 300233.SZChina$604M-31%+2%4%1.2×-0.6%-1.6%
DBV Technologies DBV.PAFrance$604M-46%n/an/an/an/an/a
Cullinan Therapeutics CGEMUnited States$585M-37%n/an/an/an/an/a
GuiZhou SanLi Pharmaceutical 603439.SSChina$583M-20%-6%5%2.6×20.9%+21.9%
Chongkundang 185750.KSSouth Korea$609M-27%+6%4%0.5×-6.6%+5.4%
Luoxin Pharmaceuticals Group Stock 002793.SZChina$609M-26%-10%-9%2.0×-1.0%-17.9%
Achieve Life Sciences QUITUnited States$609Mn/an/an/an/an/an/a
HeiLongJiang ZBD Pharmaceutical 603567.SSChina$610M-39%-82%n/a25.1×9.1%-25.1%
Zhejiang Anglikang Pharmaceutical 002940.SZChina$612M-52%-13%10%3.3×10.1%+2.1%
Fuan Pharmaceutical (Group) 300194.SZChina$612M-14%-3%-1%2.4×10.9%-5.9%
Lepu Biopharma 2157.HKHong Kong$580M-43%+47%7%4.5×n/an/a
Oneness Biotech 4743.TWOTaiwan$580M-13%+19%-589%101.5×n/an/a
Orchid Pharma ORCHPHARMA.NSIndia$613M+30%+11%0%6.1×n/an/a
TTY Biopharm 4105.TWOTaiwan$615M+10%+5%29%3.0×-8.7%+8.8%
Abbisko Cayman 2256.HKHong Kong$578M-39%-83%-520%20.1×n/an/a
Beijing Tong Ren Tang Chinese Medicine 3613.HKHong Kong$577M-26%-21%32%1.9×-15.4%+2.8%
Olema Pharmaceuticals OLMAUnited States$619M-49%n/an/an/an/an/a

Questions

Which companies are Immix Biopharma's closest peers?
The cockpit's peer set: JIANMIN PHARMACEUTICAL (600976.SS), Xiangxue Pharmaceutical (300147.SZ), Hangzhou Bio-Sincerity Pharma-Tech (301096.SZ), Shandong Jincheng Pharmaceutical (300233.SZ), DBV Technologies (DBV.PA), Cullinan Therapeutics (CGEM), GuiZhou SanLi Pharmaceutical (603439.SS), Chongkundang (185750.KS).
How has Immix Biopharma stock performed?
Over six months to 18 Nov 2026 the shares returned -20.5% against -31.3% for the median peer; over one year +76.0%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.